Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus adalimumab biosimilar for radiographic progression in active ankylosing spondylitis
NL-OMON55618Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of secukinumab and adalimumab in ankylosing spondylitis (AS) (2 arms), sponsored by Novartis. Primary endpoint: No radiographic progression at Week 104. Started Jan 2019; status: recruiting.
02
Drugs
secukinumabadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON55618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55618.